| Index | — | P/E | 11.60 | EPS (ttm) | 2.31 | Insider Own | 1.53% | Shs Outstand | 109.25M | Perf Week | 5.76% |
| Market Cap | 2.93B | Forward P/E | — | EPS next Y | -2.13 | Insider Trans | -9.16% | Shs Float | 104.05M | Perf Month | 14.82% |
| Enterprise Value | 1.94B | PEG | — | EPS next Q | -0.46 | Short Float | 19.81% | Perf Quarter | 15.42% | ||
| Income | 295.00M | P/S | 4.17 | EPS this Y | — | Short Ratio | 14.20 | Perf Half Y | 59.43% | ||
| Sales | 702.00M | P/B | 3.02 | EPS next Y | -190.38% | ROA | 24.67% | Short Interest | 20.61M | Perf YTD | 41.28% |
| Book/sh | 8.86 | P/C | 2.79 | EPS next 5Y | — | ROE | 49.34% | 52W High | 28.23 -8.96% | Perf Year | 129.06% |
| Cash/sh | 9.59 | P/FCF | 7.93 | EPS past 3/5Y | — | ROIC | 25.95% | 52W Low | 11.50 123.48% | Perf 3Y | 530.59% |
| Dividend Est. | — | EV/EBITDA | 6.01 | Sales past 3/5Y | 29.14% 36.08% | Gross Margin | 86.50% | Volatility | 5.15% 5.06% | Perf 5Y | -4.46% |
| Dividend TTM | — | EV/Sales | 2.77 | EPS Y/Y TTM | — | Oper. Margin | 41.27% | ATR (14) | 1.20 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 8.44 | Sales Y/Y TTM | 745.78% | Profit Margin | 42.01% | RSI (14) | 63.81 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 8.44 | EPS Q/Q | 559.22% | SMA20 | 9.07% | Beta | 1.75 | Target Price | 35.58 |
| Payout | 0.00% | Debt/Eq | 0.06 | Sales Q/Q | 8312.50% | SMA50 | 7.28% | Rel Volume | 1.34 | Prev Close | 26.80 |
| Employees | 317 | LT Debt/Eq | 0.06 | Earnings | Feb 17 | SMA200 | 32.83% | Avg Volume | 1.73M | Price | 25.70 |
| IPO Date | Jul 24, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | — | Net Debt/EBITDA | -3.05 | Volume | 2,311,432 | Change | -4.10% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-16-26 | Reiterated | HC Wainwright & Co. | Buy | $34 → $36 |
| Oct-13-26 | Reiterated | Robert W. Baird | $33 → $36 | |
| Oct-13-26 | Reiterated | Stifel Nicolaus | $40 → $41 | |
| Oct-13-26 | Reiterated | Truist Securities | Buy | $34 → $33 |
| Oct-13-26 | Reiterated | Oppenheimer | Outperform | $28 → $32 |
| Oct-13-26 | Reiterated | RBC Capital | Outperform | $33 → $35 |
| Jul-28-26 | Reiterated | Morgan Stanley | Overweight | $36 → $38 |
| Jul-22-26 | Reiterated | UBS | Buy | $23 → $31 |
| Jul-13-26 | Reiterated | Mizuho | Outperform | $34 |
| Jul-10-26 | Reiterated | Stifel Nicolaus | $34 → $40 |
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 11/30/2025 | FY 2024 11/30/2024 | FY 2023 11/30/2023 | FY 2022 11/30/2022 | FY 2021 11/30/2021 | FY 2020 11/30/2020 | FY 2019 11/30/2019 | FY 2018 11/30/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 702 | 84 | 55 | 77 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 95 | 19 | 222 | 189 | — | — | — | — | — | |
| Gross Profit | 607 | 65 | -167 | -112 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 79 | 53 | 46 | 43 | — | — | — | — | — | |
| Research and Development | 332 | 308 | 222 | 189 | — | — | — | — | — | |
| Other Operating Expense | -94 | -10 | -222 | -189 | — | — | — | — | — | |
| Operating Income | 290 | -286 | -213 | -155 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 18 | 22 | 20 | 11 | — | — | — | — | — | |
| Net Income Before Taxes | 308 | -264 | -193 | -144 | — | — | — | — | — | |
| Income Taxes | 14 | 1 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | 295 | -264 | -194 | -144 | — | — | — | — | — | |
| Net Income From Continuing Operations | 295 | -264 | -194 | -144 | — | — | — | — | — | |
| Net Income | 295 | -264 | -194 | -144 | — | — | — | — | — | |
| EPS (Recurring) | 2.51 | -3.05 | -2.88 | -2.65 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 2.51 | -3.05 | -2.88 | -2.65 | — | — | — | — | — | |
| EPS (Diluted) | 2.31 | -3.05 | -2.88 | -2.65 | — | — | — | — | — | |
| EBITDA | 323 | -245 | -177 | -130 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 11.13 | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.10 | 18.31 | 26.93 | 4.36 | — | — | — | — | — | |
| Gross Margin | 86.47 | 77.38 | -303.64 | -145.45 | — | — | — | — | — | |
| Operating Margin | 41.31 | -340.48 | -387.27 | -201.30 | — | — | — | — | — | |
| Net Margin | 42.02 | -314.29 | -352.73 | -187.01 | — | — | — | — | — | |
| Shares Outstanding | 112 | 87 | 67 | 54 | — | — | — | — | — | |
| Market Capitalization | 2,878 | 1,538 | 1,481 | 336 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hansen Gwenn | Chief Scientific Officer | Oct 15 '26 | Sale | 25.00 | 1,452 | 36,300 | 117,227 | Oct 15 |
| Hansen Gwenn | Chief Scientific Officer | Oct 15 '26 | Option Exercise | 1.86 | 1,452 | 2,701 | 118,679 | Oct 15 |
| GREGORY JULIA P | Director | Oct 14 '26 | Sale | 23.40 | 22,583 | 528,528 | 10,750 | Oct 14 |
| GREGORY JULIA P | Director | Oct 14 '26 | Option Exercise | 1.86 | 22,583 | 42,004 | 33,333 | Oct 14 |
| Ring Christine | Chief Legal Officer | Oct 02 '26 | Sale | 23.19 | 5,786 | 134,149 | 9,110 | Oct 02 |
| Ring Christine | Chief Legal Officer | Oct 02 '26 | Option Exercise | 8.72 | 5,786 | 50,454 | 14,896 | Oct 02 |
| Ring Christine | Chief Legal Officer | Sep 02 '26 | Option Exercise | 8.72 | 5,787 | 50,463 | 14,897 | Sep 02 |
| Ring Christine | Chief Legal Officer | Sep 02 '26 | Sale | 25.76 | 5,787 | 149,072 | 9,110 | Sep 02 |
| Hansen Gwenn | Chief Scientific Officer | Sep 01 '26 | Sale | 25.47 | 1,452 | 36,982 | 117,227 | Sep 01 |
| Hansen Gwenn | Chief Scientific Officer | Sep 01 '26 | Option Exercise | 1.86 | 1,452 | 2,701 | 118,679 | Sep 01 |
| Hansen Gwenn | Chief Scientific Officer | Aug 05 '26 | Option Exercise | 1.86 | 4,356 | 8,102 | 121,583 | Aug 05 |
| Hansen Gwenn | Chief Scientific Officer | Aug 05 '26 | Sale | 25.00 | 4,356 | 108,900 | 117,227 | Aug 05 |
| Hansen Gwenn | Chief Scientific Officer | Aug 04 '26 | Sale | 24.36 | 4,111 | 100,142 | 117,227 | Aug 05 |
| van Houte Hans | Chief Financial Officer | Aug 04 '26 | Sale | 24.36 | 4,761 | 115,990 | 40,166 | Aug 04 |
| Ring Christine | Chief Legal Officer | Aug 03 '26 | Option Exercise | 8.72 | 5,787 | 50,463 | 25,699 | Aug 03 |